Jinxin Xu - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jinxin Xu

Showing results (71-80 of 74) with videos related to

Pageof 8

Sort By:

You have reached the last page of results.This site can display upto 74 results.

Nature Communications|January 8, 2025

Defining ortholog-specific UHRF1 inhibition by STELLA for cancer therapyWenjing Bai, Jinxin Xu, Wenbin Gu, et al.

Nature Communications|May 9, 2025

Targeted disruption of PRC1.1 complex enhances bone remodelingLiangyu Xing, Jinxin Xu, Meihan Gong, et al.

Nature Communications|December 8, 2025

Monitoring rapid degradation of NANOG reveals UTP15 maintains pluripotency by regulating nascent transcriptsMingqiang Deng, Dongmei He, Xiwei Wang, et al.

Nature Microbiology|March 30, 2024

Preclinical evaluation of the SARS-CoV-2 M<sup>pro</sup> inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvirXiaoxin Chen, Xiaodong Huang, Qinhai Ma, et al.

Pageof 8

Search research articles

Showing results (71-80 of 74) with videos related to

Sort By:

Pageof 8

You have reached the last page of results.This site can display upto 74 results.

Nature Communications|January 8, 2025

Defining ortholog-specific UHRF1 inhibition by STELLA for cancer therapyWenjing Bai, Jinxin Xu, Wenbin Gu, et al.

Nature Communications|May 9, 2025

Targeted disruption of PRC1.1 complex enhances bone remodelingLiangyu Xing, Jinxin Xu, Meihan Gong, et al.

Nature Communications|December 8, 2025

Monitoring rapid degradation of NANOG reveals UTP15 maintains pluripotency by regulating nascent transcriptsMingqiang Deng, Dongmei He, Xiwei Wang, et al.

Nature Microbiology|March 30, 2024

Preclinical evaluation of the SARS-CoV-2 M<sup>pro</sup> inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvirXiaoxin Chen, Xiaodong Huang, Qinhai Ma, et al.

Pageof 8